SG Americas Securities
CTXR icon

SG Americas Securities’s Citius Pharmaceuticals CTXR Stock Holding History

SG Americas Securities’s Portfolio CTXR Stock Details CTXR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1,641
Closed -$37K – 2939
2024
Q1 		$37K Sell
1,641
-882
-35% -$16.1K ﹤0.01% 2810
2023
Q4 		$48K Buy
2,523
+218
+9% +$4.13K ﹤0.01% 2925
2023
Q3 		$39K Buy
+2,305
New +$54.8K ﹤0.01% 2979
2022
Q4 		– Sell
-3,579
Closed -$108K – 3112
2022
Q3 		$108K Buy
+3,579
New +$98.4K ﹤0.01% 2809
2022
Q2 		– Sell
-561
Closed -$25K – 3447
2022
Q1 		$25K Sell
561
-618
-52% -$24.4K ﹤0.01% 2879
2021
Q4 		$45K Sell
1,179
-1,753
-60% -$79.5K ﹤0.01% 3201
2021
Q3 		$149K Buy
+2,932
New +$147K ﹤0.01% 3441

Other funds holding CTXR

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SG Americas Securities's CTXR Position: Q2 2024 in Review

SG Americas Securities sold out of Citius Pharmaceuticals (CTXR) in Q2 2024, closing a stake of 1,641 shares — an estimated $37K sold.

SG Americas Securities first reported a position in CTXR in Q3 2021 and held it in 7 quarters. The position peaked at $149K in Q3 2021. 72 funds tracked by Wall St. Rank hold CTXR as of Q2 2024.

  • SG Americas Securities reported no remaining Citius Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • SG Americas Securities sold 1,641 Citius Pharmaceuticals shares in Q2 2024, an estimated $37K.
  • SG Americas Securities first reported a position in Citius Pharmaceuticals in Q3 2021 and held it in 7 quarters.
  • SG Americas Securities's Citius Pharmaceuticals position peaked at $149K in Q3 2021.
  • 72 funds tracked by Wall St. Rank held Citius Pharmaceuticals as of Q2 2024.

Based on SG Americas Securities's 13F filing for Q2 2024, filed 12 Jul 2024.